NCT07083427

CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)

CAPA In-vitro Oocyte Maturation

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Conditions

• Infertility, Female

Interventions

Type	Name	Description
OTHER	CAPA-IVM	In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Timeline

• Start date: 2025-08-01
• Primary completion: 2035-06-30
• Completion: 2036-07-01
• First posted: 2025-07-24
• Last updated: 2025-07-24

Locations

1 site across 1 country: Hong Kong